Arranta Bio has completed an $82 million funding round and formed a strategic partnership with Thermo Fisher Scientific.   Formed in May 2019, Arranta’s goal is to be the best-in-class microbiome contract development and manufacturing organization (CDMO). The business provides live biopharmaceutical products (LBPs) for microbiome pioneers by bacterial fermentation, isolation, drying and encapsulation.   Arranta’s funding round was completed with sole institutional investor, Ampersand...